Trou­bled Te­va poach­es Lund­beck CEO Schultz with an of­fer he could­n't refuse, in­clud­ing $20M in cash

A lit­tle more than two years af­ter No­vo Nordisk heir ap­par­ent Kåre Schultz jumped ship for the top job at Lund­beck, he’s mov­ing on to take the helm at a storm-tossed Te­va Phar­ma­ceu­ti­cal. Schultz will al­so re­main in the CEO spot at Lund­beck un­til the Dan­ish bio­phar­ma play­er can find a new CEO of its own.

And that’s not all. Co­in­ci­den­tal­ly chief com­mer­cial of­fi­cer Staffan Schüberg is al­so leav­ing Lund­beck and tak­ing over at a pri­vate­ly-held com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER